Skip to content

Effect of Angiotensin Receptor Blockade on Insulin Resistance and Adipose Tissue Cytokines in Type 2 Diabetes

Effect of Acute Angiotensin Receptor Blockade on Insulin Resistance and Selected Cytokines in Adipose Tissue in Type 2 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01011062
Enrollment
23
Registered
2009-11-11
Start date
2004-01-31
Completion date
2009-08-31
Last updated
2013-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Type 2 Diabetes

Keywords

Adipose tissue, Adipokines

Brief summary

The study aims to investigate the effect of acute angiotensin receptor blockade on insulin action/insulin resistance and expressions of selected adipocytokines in subcutaneous adipose tissue in insulin-resistant subjects with type 2 diabetes and healthy controls. Hypothesis: Changes in adipocytokine concentrations and/or expressions and different reactions to acute in vivo induced hyperinsulinemia and angiotensin receptor blockade will be found in patients with type 2 diabetes compared to healthy subjects. A significant relationships between insulin sensitivity and selected adipokines and intracellular fat content and high energy phosphates in soleus muscle will be documented in healthy individuals, while no significant relation will be found in patients with type 2 diabetes.

Detailed description

10-15 patients with type 2 diabetes and 10-15 healthy control subjects will be examined on an outpatient basis. The following examination will be carried out in each subject after 12 hrs fasting: * Oral glucose tolerance test (75 g of glucose) (in healthy subjects to confirm the normal tolerance of glucose). * Evaluation of insulin secretion after 1 mg of glucagon i.v. * Hyperinsulinaemic (75 milly-international unit(mIU)/l) euglycemic clamp study lasting 4 hours combined with indirect calorimetry and biopsy of subcutaneous adipose tissue. * Hyperinsulinemic (75 mIU/l) euglycemic clamp study lasting 4 hours combined with indirect calorimetry after losartan 100 mg given in the evening and in the morning before the study. * Proton and phosphorus magnetic resonance spectroscopy. Before (0 min), at 30 min and in the end of studies c) and d) the blood samples will be taken and biopsies of subcutaneous abdominal adipose tissue will be done.

Interventions

PROCEDUREHyperinsulinaemia

Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp

DRUGLosartan

Acute administration of losartan 200mg total prior to clamp

DRUGSaline

Infusion of Saline as a volume control intervention

Sponsors

Ministry of Health, Czech Republic
CollaboratorOTHER_GOV
Institute for Clinical and Experimental Medicine
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

1. Type 2 Diabetes treated with oral agents and/or diet 2. Healthy volunteers age- and sex-matched to type 2 diabetes, without any concomitant disease

Exclusion criteria

1. Type 2 Diabetes * treated with insulin * clinical evidence of atherosclerotic complications * advanced long-term diabetic complications (manifest nephropathy, proliferative retinopathy) * other internal disease * weight change \>10% 3 months prior to study 2. Healthy volunteers * fulfilling the criteria of metabolic syndrome * weight change \>10% 3 months prior to study

Design outcomes

Primary

MeasureTime frame
insulin sensitivity measured as glucose disposal during clamp4 hours

Secondary

MeasureTime frame
plasma adipokines and their expressions in SATat 0 and 240 min of the clamp

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026